Affinity: Hospital Trial

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

NCT01776684 ·Status: UNKNOWN ·Phase: NA

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

NCT01610336 ·Status: COMPLETED ·Phase: PHASE2

Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

NCT05810350 ·Status: UNKNOWN ·Phase: PHASE2

Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

NCT02747953 ·Status: COMPLETED ·Phase: PHASE2

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

NCT05017025 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00517790 ·Status: COMPLETED ·Phase: PHASE2

A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer

NCT00090701 ·Status: WITHDRAWN ·Phase: PHASE2

Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)

NCT00568841 ·Status: UNKNOWN ·Phase: PHASE2

Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment

NCT00673569 ·Status: COMPLETED ·Phase: PHASE2

Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone

NCT01513174 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients

NCT04912687 ·Status: COMPLETED ·Phase: NA

Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity

NCT02183883 ·Status: COMPLETED ·Phase: PHASE2

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

NCT04780568 ·Status: RECRUITING ·Phase: PHASE1

Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients

NCT01415011 ·Status: COMPLETED ·Phase: PHASE2

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

NCT06562192 ·Status: RECRUITING ·Phase: PHASE1

Development of Circulating Tumour Cell Molecular Diagnostics Using a Novel Microfluidic Device

NCT01193829 ·Status: UNKNOWN

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT02296125 ·Status: COMPLETED ·Phase: PHASE3

A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma

NCT04629209 ·Status: WITHDRAWN ·Phase: PHASE2

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC

NCT01772732 ·Status: UNKNOWN ·Phase: PHASE1

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

NCT02414139 ·Status: COMPLETED ·Phase: PHASE2

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

NCT01998126 ·Status: COMPLETED ·Phase: PHASE1

Combination of Chemotherapy and Gefitinib as First-line Treatment

NCT02148380 ·Status: COMPLETED ·Phase: NA

A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

NCT04636593 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

NCT01887886 ·Status: COMPLETED ·Phase: PHASE3

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

NCT02088112 ·Status: COMPLETED ·Phase: PHASE1